Antonio Cuevas-Navarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonio Cuevas-Navarro has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Pau Castel
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
17 shared publications - Anatoly Urisman
Department of Pathology, University of California San Francisco, San Francisco, California
10 shared publications - Frank McCormick
University of California, San Francisco 9 Helen Diller Family Comprehensive Cancer Center San Francisco, California
10 shared publications - Alessandro M. Mozzarelli
Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, New York
7 shared publications - Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
7 shared publications - Dmitri A. Petrov
Department of Biology, Stanford University, Stanford, CA 94305, USA
7 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Demographics of RIT1 mutant NSCLC
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Demographics of RIT1 mutant NSCLC
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S2 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Analysis of tumors and genes involved in RIT1 tumorigenesis
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S2 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Analysis of tumors and genes involved in RIT1 tumorigenesis
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors.Significance:RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors.See related commentary by Wu and Vaishnavi, p. 3186See related article by DiMarco et al., p. 3207
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors.Significance:RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors.See related commentary by Wu and Vaishnavi, p. 3186See related article by DiMarco et al., p. 3207
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S4 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of RAS(ON) inhibitor in RIT1-driven models
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S4 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of RAS(ON) inhibitor in RIT1-driven models
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S3 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of MAPK and RAS exchange inhibition in RIT1-driven models
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S3 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of MAPK and RAS exchange inhibition in RIT1-driven models
- 11 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (17) , 3196-3206
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors. Significance: RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by DiMarco et al., p. 3207
- 11 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (17) , 3196-3206
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors. Significance: RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by DiMarco et al., p. 3207
- Open Access
- 30 October 2024
- Published by Springer Nature in Nature
- Vol. 637 (8044) , 224-229
Pharmacological restoration of GTP hydrolysis by mutant RAS
Approximately 3.4 million patients worldwide are diagnosed each year with cancers that harbor pathogenic mutations in one of three RAS proto-oncogenes (KRAS, NRAS and HRAS)1,2. These mutations impair the GTPase activity of RAS, leading to activation of downstream signaling and proliferation3-6. Long-standing efforts to restore the hydrolase activity of RAS mutants have been unsuccessful, extinguishing any consideration towards a viable therapeutic strategy7. Here we show that tri-complex inhibitors, that is, molecular glues with the ability to recruit cyclophilin A (CYPA) to the active state of RAS have a dual mechanism of action: not only do they prevent activated RAS from binding to its effectors, but, unexpectedly, they also stimulate GTP hydrolysis. Drug-bound CYPA complexes modulate residues in the switch II motif of RAS to coordinate the nucleophilic attack on the ɣ phosphate of GTP, in a mutation-specific manner. RAS mutants most sensitive to stimulation of GTPase activity were more susceptible to treatment compared to mutants whose hydrolysis could not be enhanced, suggesting that pharmacologic stimulation of hydrolysis potentiates the therapeutic effects of tri-complex inhibitors for specific RAS mutants. This study lays the foundation for developing a new class of therapeutics that inhibit cancer growth by stimulating mutant GTPase activity.
- 30 October 2024
- Published by Springer Nature in Nature
- Vol. 637 (8044) , 224-229
Open AccessPharmacological restoration of GTP hydrolysis by mutant RAS
Approximately 3.4 million patients worldwide are diagnosed each year with cancers that harbor pathogenic mutations in one of three RAS proto-oncogenes (KRAS, NRAS and HRAS)1,2. These mutations impair the GTPase activity of RAS, leading to activation of downstream signaling and proliferation3-6. Long-standing efforts to restore the hydrolase activity of RAS mutants have been unsuccessful, extinguishing any consideration towards a viable therapeutic strategy7. Here we show that tri-complex inhibitors, that is, molecular glues with the ability to recruit cyclophilin A (CYPA) to the active state of RAS have a dual mechanism of action: not only do they prevent activated RAS from binding to its effectors, but, unexpectedly, they also stimulate GTP hydrolysis. Drug-bound CYPA complexes modulate residues in the switch II motif of RAS to coordinate the nucleophilic attack on the ɣ phosphate of GTP, in a mutation-specific manner. RAS mutants most sensitive to stimulation of GTPase activity were more susceptible to treatment compared to mutants whose hydrolysis could not be enhanced, suggesting that pharmacologic stimulation of hydrolysis potentiates the therapeutic effects of tri-complex inhibitors for specific RAS mutants. This study lays the foundation for developing a new class of therapeutics that inhibit cancer growth by stimulating mutant GTPase activity.
- Top Cited PapersOpen Access
- 8 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8013) , 919-926
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985).
- 8 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8013) , 919-926
Top Cited PapersOpen AccessConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985).
- Top Cited Papers
- 18 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6659) , 794-799
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).
- 18 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6659) , 794-799
Top Cited PapersChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).